Synergistic Fungistatic Effects of Lactoferrin in Combination with Antifungal Drugs against Clinical Candida Isolates
- 1 November 1999
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 43 (11) , 2635-2641
- https://doi.org/10.1128/aac.43.11.2635
Abstract
Because of the rising incidence of failures in the treatment of oropharyngeal candidosis in the case of severely immunosuppressed patients (mostly human immunodeficiency virus [HIV]-infected patients), there is need for the development of new, more effective agents and/or compounds that support the activity of the common antifungal agents. Since lactoferrin is one of the nonspecific host defense factors present in saliva that exhibit antifungal activity, we studied the antifungal effects of human, bovine, and iron-depleted lactoferrin in combination with fluconazole, amphotericin B, and 5-fluorocytosine in vitro against clinical isolates ofCandida species. Distinct antifungal activities of lactoferrin were observed against clinical isolates ofCandida. The MICs generally were determined to be in the range of 0.5 to 100 mg · ml−1. Interestingly, in the combination experiments we observed pronounced cooperative activity against the growth of Candida by using lactoferrin and the three antifungals tested. Only in a limited concentration range was minor antagonism detected. The use of lactoferrin and fluconazole appeared to be the most successful combination. Significant reductions in the minimal effective concentrations of fluconazole were found when it was combined with a relatively low lactoferrin concentration (1 mg/ml). Such combinations still resulted in complete growth inhibition, while synergy of up to 50% against several Candida species was observed. It is concluded that the combined use of lactoferrin and antifungals against severe infections with Candida is an attractive therapeutic option. Since fluconazole-resistantCandida species have frequently been reported, especially in HIV-infected patients, the addition of lactoferrin to the existing fluconazole therapy could postpone the occurrence of species resistance against fluconazole. Clinical studies to further elucidate the potential utility of this combination therapy have been initiated.Keywords
This publication has 46 references indexed in Scilit:
- Plasma Lactoferrin Levels Are Decreased in End-Stage AIDS PatientsViral Immunology, 1999
- Augmented inhibition of growth ofCandida albicansby neutrophils in the presence of lactoferrinFEMS Immunology & Medical Microbiology, 1997
- Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infectionJournal of Antimicrobial Chemotherapy, 1996
- Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cellsAntiviral Research, 1996
- Fluconazole therapy of oral candidiasis in HIV-infected patients: Results of a multicentre studyInfection, 1994
- Systemically Administered Antifungal AgentsDrugs, 1992
- Fungicidal effect of human lactoferrin against Candida albicansFEMS Microbiology Letters, 1992
- Fungicidal effect of human lactoferrin againstCandida albicansFEMS Microbiology Letters, 1992
- Amphotericin B: 30 Years of Clinical ExperienceClinical Infectious Diseases, 1990
- Lactoferrin in human milk: its role in iron absorption and protection against enteric infection in the newborn infant.Archives of Disease in Childhood, 1980